Document is current
Any future updates will be listed below
-
Authors
Hagino, Hiroshi https://orcid.org/0000-0001-8053-1095
Moriwaki, Kenta
Wada, Takashi
Osaki, Mari
Nagashima, Hideki
Matsumoto, Hiromi
-
Funding
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science, and Technology Grant-in-Aid for Scientific Research
School of Health Sciences, Faculty of Medicine, Tottori University
JSPS KAKENHI
- License Information
-
More Information
Article History
Received: 20 January 2023
Accepted: 30 May 2023
First Online: 8 June 2023
Declarations
:
: HH received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. HN received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Johnson & Johnson K.K., Kyocera Corp., Medtronic, NuVasive Inc., Nippon Zoki Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Teijin Nakashima Medical Co., Ltd., and Kaken Pharmaceutical Co., Ltd.KM, TW, MO, and HM declare that they have no competing interests.
